PCSK9
Sort by:
The American Society for Preventive Cardiology
Updated Approach to Risk Assessment and Shared Decision Making
FEATURING
Laurence Sperling
- 1,007 views
- January 23, 2019
- 3
Cardiometabolic Health Congress (CMHC)
Non-Statin Drugs and New Approaches
FEATURING
Marc Sabatine,
Christie Ballantyne
- 1,028 views
- January 10, 2019
- 6
Cardiometabolic Health Congress (CMHC)
Triglycerides and Cardiovascular Disease
- 436 views
- January 10, 2019
- 3
Cardiometabolic Health Congress (CMHC)
Audience Q&A: The ABC Access Program
- 29 views
- January 10, 2019
Cardiometabolic Health Congress (CMHC)
Real World Approaches to Access: A Clinician’s Perspective
FEATURING
Deirdre Mattina,
Keith Ferdinand
- 24 views
- January 10, 2019
Cardiometabolic Health Congress (CMHC)
The ABC Access Program: Actions Taken, Current Status and Future Considerations
FEATURING
Keith Ferdinand
- 125 views
- January 10, 2019
Cardiovascular Disease Management: A Case-Based Approach 2018
Can Heart Disease Be Abolished? The PCSK9 Revolution
FEATURING
Christie Ballantyne
- 397 views
- December 21, 2018
- 2
Northwestern Medicine Cardiovascular Care
Clyde W. Yancy, MD and Neil J. Stone, MD Discuss New Cardiovascular Guidelines at AHA Scientific Sessions 2018
FEATURING
Clyde Yancy,
Neil Stone
- 541 views
- December 20, 2018
- 5
Advances in Cardiovascular Disease Prevention
Paradigm Shifts: Understanding and Applying the Latest Lipid Guidelines
FEATURING
Andrew Freeman
- 1,336 views
- October 22, 2018
- 6
The American Society for Preventive Cardiology
Preventive Cardiology Now and 5 Years From Now, a Strategic Vision
FEATURING
Sergio Fazio
- 238 views
- August 10, 2018
- 1
ASPC 2018 Congress on CVD Prevention
Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App and More - A Town Hall Series - The App
FEATURING
Seth Baum
- 151 views
- August 10, 2018
ASPC 2018 Congress on CVD Prevention
PCSK9 Inhibitors Today - When, How, and In Whom
FEATURING
Jennifer Robinson
- 491 views
- August 10, 2018
- 3
ASPC 2018 Congress on CVD Prevention
Debate – Con – Lipoprotein(a) – There is Nothing You Can Do About It So Why Measure?
FEATURING
Sergio Fazio
- 334 views
- August 10, 2018
- 1
ASPC 2018 Congress on CVD Prevention
Debate – Pro – Lipoprotein(a) – Should Be Measured In All Patients At Higher CVD Risk
FEATURING
Patrick Moriarty
- 836 views
- August 10, 2018
- 10
Cardiometabolic Health Congress (CMHC)
Ensuring Access to Evidence: Based Therapies in High Risk Special Populations
FEATURING
Catherine Davis
- 59 views
- May 7, 2018